Carboxylic acid compounds

Details Carboxylic acid compounds Carboxylic acid compounds

2004-02-06

2009-08-18

Andres, Janet L. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S563000, C546S329000, C549S013000, C549S032000, C549S059000, C549S074000, C549S426000, C549S434000, C549S445000, C549S469000, C560S021000, C562S405000

Reexamination Certificate

active

07576129

ABSTRACT:
The present invention relates to a carboxylic acid compound of formula (I):wherein R1is H, alkyl; m is 2, 3; n is 0-2; R2is phenyl, naphthyl, benzofuran, benzothiophene; Q is —CH2—O-Cyc1, —CH2-Cyc2, -L-Cyc3; R3aand R3beach independently is hydrogen, alkyl or taken together form tetrahydro-2H-pyran; a pharmaceutically acceptable salt thereof, a method for producing a process of the preparation thereof and a pharmaceutical agent comprising the same as an active ingredient. The compound of formula (I) have an antagonizing activity against PGE2receptor, specifically EP3receptor which is subtype thereof, and are useful for the prevention and/or treatment of itching, pain, urinary disturbance or stress disease.

REFERENCES:
patent: 3950393 (1976-04-01), Keck et al.
patent: 5716993 (1998-02-01), Ozaki et al.
patent: 6018068 (2000-01-01), Nagao et al.
patent: 6043275 (2000-03-01), Maruyama et al.
patent: 6462081 (2002-10-01), Maruyama et al.
patent: 1642594 (2006-04-01), None
patent: WO 02/16311 (2002-02-01), None
patent: WO 02/100403 (2002-12-01), None
patent: WO 03/016254 (2003-02-01), None
Minami, Toshiaki, et al.; Characterization of EP Receptor Subtypes Responsible for Prostaglandin E2-induced Pain Responses by Use of EP1 and EP3 Receptor Knockout Mice; British Journal of Pharmacology (2001) 133,438-444.
Schüβler, B. Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2- derivative on the lower urinary tract in healthy women Urological Research vol. 18, No. 5 349-352, 1990.
Nakamura, K. et al., Prostaglandin EP3 Receptor Protein in Serotonin And Catecholamine Cell Groups: A Double Immunofluorescence Study In The Rat Brain, Neuroscience 2001;103 vol. (3)- pp. 763-775.
Nasushita, R. et al., A Comparative Study of Adrenocorticotropin-releasing activity of prostaglanding E1, E1, F2? and D2 In The Rat; The Japanese Journal of Pharmacology vol. 79 suppl. I p. 87 Prostaglandins Leukot Essent Fatty Acids Feb. 1997 56(2):165-8.
Nishigaki Nobuhiro, et al.; Characterization of the Prostaglandin E Receptor Expressed on a Cultured Mast Line, BNu-2cl3; CellBiochem Pharmacol. Sep. 1, 1993;46(5):863-9.
Fedyk Eric, R. ,et al., Prostaglandin E2 Receptors of the EP2 and EP4 Subtypes Regulate Activation and Differentiation of Mouse B Lymphocytes to IgE-secreting Cells; Proc Natl Acad Sci USA. Oct. 1, 1996;93(20):10978-83.
Gomi Kaede et al.; Prostaglandin E2 Selectively Enhances the IgE-Mediated Production of IL-6 and Granulocyte-Macrophage Colony-Stimulationg Factor by Mast Cells Trough an EP1/EP3-Dependent Mechanism; The Journal of Immunology, 2000, 165:6545-6552.

Affiliated with

Also associated with

Rating

Carboxylic acid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Carboxylic acid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxylic acid compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4052980